Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis
NCT ID: NCT00086164
Last Updated: 2005-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
INTERVENTIONAL
2004-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
edifoligide (E2F Decoy)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be currently receiving chronic dialysis or be expected to begin hemodialysis within 4 weeks of placement of the index PTFE graft
* Have undergone an assessment of patency (such as venography) of central veins if any of the following conditions have occurred on the ipsilateral arm intended for graft placement: presence of collateral veins, upper extremity edema or increased size (relative to the contralateral arm), history of subclavian catheter, transvenous pacemaker, or history of trauma or surgery that may have involved the neck or chest veins
* Be \> 18 and \<80 years old
* Have a documented negative serum pregnancy test (for all women of childbearing potential)
* Be using an acceptable method of birth control if of reproductive potential and agree to continue using the birth control for at least 3 months following the graft procedure
* Have agreed to participate voluntarily and have signed and dated an IRB/EC approved, Patient Informed Consent form
Exclusion Criteria
* Have a history of three or more previous PTFE grafts
* Have uncorrected central vein (including the subclavian vein) stenosis
* Have markedly diminished arterial pulses in the access location (unless adequate flow has been documented by arteriography or Doppler ultrasound)
* Anticipate receipt of a renal transplant within 6 months of enrollment into this study
* Have anticipated use of the index PTFE graft \<14 days after enrollment (this does not apply to Vectragraft®)
* Have a known allergy to iodinated contrast
* Have a known hypercoagulable state (e.g., antithrombin III deficiency; antiphospholipid or anticardiolipin antibodies; Factor V Leiden; circulating lupus anticoagulant; current, active, heparin-induced thrombocytopenia; Protein C or S deficiency; or a history of recurrent deep venous thrombosis not related to AV access)
* Have been in another investigational (i.e., nonapproved) drug or device study within the previous 30 days or prior participation in another clinical study with E2F Decoy
* Have been previously enrolled in this study for an earlier access graft
* Have any comorbid, nonrenal condition that makes 6-month survival questionable (e.g., end-stage cancer, advanced heart failure)
* Have a known or suspected history of drug or alcohol abuse within the previous 6 months
* Have a known allergy to any component of the investigational product (drug or device), including latex
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Anesiva, Inc.
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute of Clinical Research, American Medical Tower
Los Angeles, California, United States
Outcomes Research International, Inc.
Hudson, Florida, United States
University of Miami, School of Medicine
Miami, Florida, United States
Tampa General Hospital
Tampa, Florida, United States
LifeLink Transplant Institute
Tampa, Florida, United States
Emory University, Renal Division
Atlanta, Georgia, United States
University Transplant
Chicago, Illinois, United States
Stoney Island Dialysis
Chicago, Illinois, United States
Methodist Hospital, Tower Surgical
Indianapolis, Indiana, United States
Vascular Surgery Associates
Baton Rouge, Louisiana, United States
Tulane Center for Abdominal Transplant
New Orleans, Louisiana, United States
Henry Ford Hospital
Detroit, Michigan, United States
Thoracic & Cardiovascular Healthcare Foundation
Lansing, Michigan, United States
St. Louis University, Division of Nephrology
St Louis, Missouri, United States
NYU Medical Center
New York, New York, United States
St. Luke's Hospital, Department of Surgery
New York, New York, United States
University of Rochester, The Center for Vascular Disease
Rochester, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Surgical Education
Greenville, South Carolina, United States
University of Utah School of Medicine, Dept of Surgery
Salt Lake City, Utah, United States
Nephrology Clinical Research Center
Charlottesville, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CGT003-05
Identifier Type: -
Identifier Source: org_study_id